About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

By: via Business Wire

New agreement to support newborn health adds sequencing lab services to the existing extraction services collaboration

Revvity, Inc. (NYSE: RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions. This expanded relationship builds upon the previously disclosed agreement to perform DNA extraction services. Revvity will now be able to provide an integrated end-to-end solution with a localized lab facility, which will allow for accelerated extraction and sequencing services to advance the screening process for these rare conditions.

The Generation Study, a research project spearheaded by Genomics England in partnership with the National Health Service, is a landmark national initiative aimed at screening up to 100,000 newborns for more than 200 rare genetic disorders. The findings will help inform future decisions on using whole genome sequencing (WGS) in newborn screening. Proactive genomic screening could help healthcare professionals identify risks for pediatric-onset conditions sooner, enabling earlier interventions and personalized care.

“It is an honor to enhance our collaboration with Genomics England as we align to expand access to genomic sequencing in England. Our complete solution and localized lab facility help us deliver timely and reliable sequencing data in support of this critical program that strengthens newborn health,” stated Dr. Madhuri Hegde, Revvity’s senior vice president and chief scientific officer. “Revvity’s expansive global laboratory network combined with our next-generation sequencing solutions and workflows for newborn screening uniquely positions us to lead this and similar initiatives, setting a standard for future programs.”

“This collaboration is an important step forward in our mission to generate evidence on the use of genomic sequencing in newborn screening. By working with Revvity as one of our sequencing partners for the Generation Study, we can integrate sequencing alongside extraction, streamlining the process, and generating results more efficiently, helping families get answers and access to care sooner,” said Dr. Ellen Thomas, chief medical officer at Genomics England.

To learn more about Revvity’s newborn sequencing research solutions, please visit: https://www.revvity.com/category/newborn-sequencing-research

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

About Genomics England

Genomics England is a global leader in enabling genomic medicine and research, established by the United Kingdom's Department of Health and Social Care, focused on creating a world where everyone benefits from genomic healthcare. Building on the 100,000 Genomes Project, it supports the NHS’s world-first national whole genome sequencing service and runs the growing National Genomic Research Library, alongside delivering numerous major genomics initiatives including the Generation Study. By connecting research and clinical care at national scale, it enables immediate healthcare benefits and advances for the future.

Contacts

More News

View More
Meta Debuts Next-Gen AI Glasses—A Turning Point for Reality Labs?
Via MarketBeat
Topics Artificial Intelligence
Tickers AAPL META
How IREN is Building an AI Powerhouse on a Bitcoin Foundation
Via MarketBeat
Topics Artificial Intelligence Supply Chain
Tickers IREN NVDA
3 Healthcare Stocks Using AI to Drive Growth
Via MarketBeat
Topics Artificial Intelligence
Tickers BSX HIMS TEM
Get Exposure to Millennials' Purchasing Power With This ETF
Via MarketBeat
Topics ETFs
Tickers AAPL DASH DIS GOOGL META MILN
Why a $4.5 Billion Smart Debt Move Is Fueling Dell’s AI Ambitions
Via MarketBeat
Topics Artificial Intelligence
Tickers DELL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.